Physiology of respiratory disturbances in muscular dystrophies

Antonella Lo Mauro, Andrea Aliverti, Antonella Lo Mauro, Andrea Aliverti

Abstract

Muscular dystrophy is a group of inherited myopathies characterised by progressive skeletal muscle wasting, including of the respiratory muscles. Respiratory failure, i.e. when the respiratory system fails in its gas exchange functions, is a common feature in muscular dystrophy, being the main cause of death, and it is a consequence of lung failure, pump failure or a combination of the two. The former is due to recurrent aspiration, the latter to progressive weakness of respiratory muscles and an increase in the load against which they must contract. In fact, both the resistive and elastic components of the work of breathing increase due to airway obstruction and chest wall and lung stiffening, respectively. The respiratory disturbances in muscular dystrophy are restrictive pulmonary function, hypoventilation, altered thoracoabdominal pattern, hypercapnia, dyspnoea, impaired regulation of breathing, inefficient cough and sleep disordered breathing. They can be present at different rates according to the type of muscular dystrophy and its progression, leading to different onset of each symptom, prognosis and degree of respiratory involvement.

Key points: A common feature of muscular dystrophy is respiratory failure, i.e. the inability of the respiratory system to provide proper oxygenation and carbon dioxide elimination.In the lung, respiratory failure is caused by recurrent aspiration, and leads to hypoxaemia and hypercarbia.Ventilatory failure in muscular dystrophy is caused by increased respiratory load and respiratory muscles weakness.Respiratory load increases in muscular dystrophy because scoliosis makes chest wall compliance decrease, atelectasis and fibrosis make lung compliance decrease, and airway obstruction makes airway resistance increase.The consequences of respiratory pump failure are restrictive pulmonary function, hypoventilation, altered thoracoabdominal pattern, hypercapnia, dyspnoea, impaired regulation of breathing, inefficient cough and sleep disordered breathing.

Educational aims: To understand the mechanisms leading to respiratory disturbances in patients with muscular dystrophy.To understand the impact of respiratory disturbances in patients with muscular dystrophy.To provide a brief description of the main forms of muscular dystrophy with their respiratory implications.

Conflict of interest statement

Conflict of interest None declared.

Figures

Figure 1
Figure 1
Representative, schematic diagram showing the pressure–volume curves of the respiratory system (RS, blue curves) and its two components, i.e. the chest wall (CW, green curves) and lung (L, red curves), for healthy subjects (thin curves on the left panel) and patients with muscular dystrophy (thick curves on the right panel). The maximal inspiratory pressure (PImax) is also reported (dashed curves). Muscular dystrophy patients are characterised by 1) reduced total lung capacity (TLC); 2) reduced compliance of chest wall (CCW), lungs (CL) and respiratory system (slope of the corresponding pressure–volume curves); 3) reduced PImax; 4) reduced inspiratory capacity (IC=TLC−FRC); and 5) reduced expiratory reserve volume (ERV=FRC−RV). Functional residual capacity (FRC) may be lower or even normal. Residual volume (RV) is not significantly different than in healthy subjects. PImax represents the force of respiratory muscles, while the volume variations are the resulting action of their contraction. The fact that PImax and lung volumes are both reduced indicates that the respiratory muscles, and therefore the respiratory pump, are affected by muscular dystrophy. The compliance of the respiratory system reduces because it decreases in both its components: 1) CL, due to lung atelectasis and fibrosis, the former being a consequence of hypoventilation, induced by respiratory muscles involvement, the latter of recurrent aspiration, induced by the involvement of bulbar muscles; and 2) CCW, due to of the onset of scoliosis, induced by the involvement of trunk muscles.
Figure 2
Figure 2
Lung volume variations during quiet breathing (grey lines) and vital capacity (blue lines) in an healthy subject (left) and a muscular dystrophy patient (right). Muscular dystrophy patients are characterised by reduced vital capacity, and rapid and shallow breathing at rest, i.e. reduced tidal volume and increased respiratory rate. RV: residual volume; FRC: functional residual capacity.
Figure 3
Figure 3
Schematic diagram summarising the generalised causes of respiratory disturbances in muscular dystrophies. Raw: airway resistance; WOBEL: elastic component of work of breathing; WOBRES: resistive component of work of breathing; ↑: increment; ↓: decrement.
Figure 4
Figure 4
a) Ribcage (top), abdominal (middle) and chest wall (bottom) volume variations during spontaneous breathing in supine position in a 17-year-old DMD patient. While tidal volume is constant, the thoracoabdominal pattern alternatively changes by passing from abdominal (<?A3B2 tic=40%?>A<?A3B2 tic?>, blue lines) to thoracic (<?A3B2 tic=40%?>B<?A3B2 tic?>, grey lines) predominance. b) “Loops” (i.e. volume changes of the abdomen versus the ribcage) in representative breaths when either the abdomen <?A3B2 tic=40%?>(A)<?A3B2 tic?> or the ribcage <?A3B2 tic=40%?>(B)<?A3B2 tic?> are prevalent. The breath of a healthy peer (control) is also reported. The arrows indicate the direction of the loops, i.e. the relative action of inspiratory ribcage muscles and the diaphragm [31]. In healthy subjects, both ribcage and abdomen expand during inspiration, with the latter being predominant. This indicates that in the supine position, the diaphragm is the leading muscle of inspiration, with a reduced contribution of ribcage muscles that mainly act to avoid chest wall distortion. The DMD patient therefore alternates periods of breathing in which inspiration is led by the diaphragm <?A3B2 tic=40%?>(A)<?A3B2 tic?> and periods in which ribcage muscles are the leading inspiratory muscles <?A3B2 tic=40%?>(B)<?A3B2 tic?>. These thoracoabdominal “alternans” are thought to be a strategy adopted to cope with diaphragmatic weakness and fatigue. Note that, however, when the diaphragm leads inspiration <?A3B2 tic=40%?>(A)<?A3B2 tic?>, its action is reduced compared to the healthy subject (i.e. reduced abdominal expansion) and this is an index of diaphragmatic weakness.

References

    1. Emery AEH. The muscular dystrophies. Lancet 2002; 359: 687–695.
    1. Perrin C, Unterborn JN, Ambrosio CD, et al. . Pulmonary complications of chronic neuromuscular diseases and their management. Muscle Nerve 2004; 29: 5–27.
    1. Allen J. Pulmonary complications of neuromuscular disease: A Respiratory mechanics perspective. Paediatr Respir Rev 2010; 11: 18–23.
    1. De Troyer A. Respiratory effect of the lower rib displacement produced by the diaphragm. J Appl Physiol 2012; 112: 529–534.
    1. Criner GJ, Marchetti N. Effects of neuromuscular diseases on ventilation. In: Grippi MA, Elias JA, Fishman JA, et al. eds. Fishman’s Pulmonary Diseases and Disorders. 5th Edn New York, McGraw-Hill Medical, 2015; pp. 1289–1311.
    1. Tzelepis GE, McCool FD. Nonmuscular diseases of the chest wall. In: Grippi MA, Elias JA, Fishman JA, et al. eds. Fishman’s Pulmonary Diseases and Disorders 5th Edn New York, McGraw-Hill Medical, 2015; pp. 1274–1287.
    1. De Troyer A, Borenstein S, Cordier R. Analysis of lung volume restriction in patients with respiratory muscle weakness. Thorax 1980; 35: 603–610.
    1. Eikermann M, Vogt FM, Herbstreit F, et al. . The predisposition to inspiratory upper airway collapse during partial neuromuscular blockade. Am J Respir Crit Care Med 2007; 175: 9–15.
    1. Ratnovsky A, Elad D, Halpern P. Mechanics of respiratory muscles. Respir Physiol Neurobiol 2008; 163: 82–89.
    1. Macklem PT. Normal and abnormal function of the diaphragm. Thorax 1981; 36: 161–163.
    1. Macklem PT. Respiratory muscles: the vital pump. Chest 1980; 78: 753–758.
    1. De Troyer A, Kelly S, Macklem PT, et al. . Mechanics of intercostal space and actions of external and internal intercostal muscles. J Clin Invest 1985; 75: 850–857.
    1. Kenyon CM, Cala SJ, Yan S, et al. . Rib cage mechanics during quiet breathing and exercise in humans. J Appl Physiol 1997; 83: 1242–1255.
    1. Aliverti A, Cala SJ, Duranti R, et al. . Human respiratory muscle actions and control during exercise. J Appl Physiol 1997; 83: 1256–1269.
    1. Laghi F, Tobin MJ. Disorders of the respiratory muscles. Am J Respir Crit Care Med 2003; 168: 10–48.
    1. Mulreany LT, Weiner DJ, McDonough JM, et al. . Noninvasive measurement of the tension-time index in children with neuromuscular disease. J Appl Physiol 2003; 95: 931–937.
    1. Misuri G, Lanini B, Gigliotti F, et al. . Mechanism of CO2 retention in patients with neuromuscular disease. Chest 2000; 117: 447–453.
    1. Bourke SC. Respiratory involvement in neuromuscular disease. Clin Med 2014; 14: 72–75.
    1. Swash M, Fox KP. Abnormal intrafusal muscle fibres in myotonic dystrophy: a study using serial sections. J Neurol Neurosurg Psychiatry 1975; 38: 91–99.
    1. Swash M, Fox KP. The pathology of the muscle spindle in Duchenne muscular dystrophy. J Neurol Sci 1976; 29: 17–32.
    1. Baydur A. Respiratory muscle strength and control of ventilation in patients with neuromuscular disease. Chest 1991; 99: 330–338.
    1. Kravitz RM. Airway clearance in Duchenne muscular dystrophy. Pediatrics 2009; 123: Suppl. 4, S231–S235.
    1. Smith JA, Aliverti A, Quaranta M, et al. . Chest wall dynamics during voluntary and induced cough in healthy volunteers. J Physiol 2012; 590: 563–574.
    1. Bersanini C, Khirani S, Ramirez A, et al. . Nocturnal hypoxaemia and hypercapnia in children with neuromuscular disorders. Eur Respir J 2012; 39: 1206–1212.
    1. Bye PT, Ellis ER, Issa FG, et al. . Respiratory failure and sleep in neuromuscular disease. Thorax 1990; 45: 241–247.
    1. D’Angelo MG, Romei M, Lo Mauro A, et al. . Respiratory pattern in an adult population of dystrophic patients. J Neurol Sci 2011; 306: 54–61.
    1. Kang PB, Morrison L, Iannaccone ST, et al. . Evidence-based guideline summary: evaluation, diagnosis, and management of congenital muscular dystrophy. Neurology 2015; 84: 1369–1378.
    1. Yonekawa T, Nishino I. Ullrich congenital muscular dystrophy: clinicopathological features, natural history and pathomechanism(s). J Neurol Neurosurg Psychiatr 2015; 86: 280–287.
    1. Kraya T, Schmidt B, Müller T, et al. . Impairment of respiratory function in late-onset distal myopathy due to MATR3 mutation. Muscle Nerve 2015; 51: 916–918.
    1. Shahrizaila N, Kinnear WJM, Wills AJ. Respiratory involvement in inherited primary muscle conditions. J Neurol Neurosurg Psychiatr 2006; 77: 1108–1115.
    1. Agostoni E, Mognoni P. Deformation of the chest wall during breathing efforts. J Appl Physiol 1966; 21: 1827–1832.
    1. Lessa TB, de Abreu DK, Bertassoli BM, et al. . Diaphragm: a vital respiratory muscle in mammals. Ann Anat 2016; 205: 122–127.
    1. LoMauro A, D’Angelo MG, Aliverti A. Assessment and management of respiratory function in patients with Duchenne muscular dystrophy: current and emerging options. Ther Clin Risk Manag 2015; 11: 1475–1488.
    1. Lo Mauro A, D’Angelo MG, Romei M, et al. . Abdominal volume contribution to tidal volume as an early indicator of respiratory impairment in Duchenne muscular dystrophy. Eur Respir J 2010; 35: 1118–1125.
    1. Toussaint M, Soudon P, Kinnear W. Effect of non-invasive ventilation on respiratory muscle loading and endurance in patients with Duchenne muscular dystrophy. Thorax 2008; 63: 430–434.
    1. Mulreany LT, Weiner DJ, McDonough JM, et al. . Noninvasive measurement of the tension-time index in children with neuromuscular disease. J Appl Physiol 2003; 95: 931–937.
    1. Lomauro A, Romei M, D’Angelo MG, et al. . Determinants of cough efficiency in Duchenne muscular dystrophy. Pediatr Pulmonol 2014; 49: 357–365.
    1. Jansen M, van Alfen N, Nijhuis van der Sanden MW, et al. . Quantitative muscle ultrasound is a promising longitudinal follow-up tool in Duchenne muscular dystrophy. Neuromuscul Disord 2012; 22: 306–317.
    1. Mavrogeni S. Cardiac and sternocleidomastoid muscle involvement in Duchenne muscular dystrophy. Chest 2005; 127: 143.
    1. Hahn A, Bach JR, Delaubier A, et al. . Clinical implications of maximal respiratory pressure determinations for individuals with Duchenne muscular dystrophy. Arch Phys Med Rehabil 1997; 78: 1–6.
    1. Phillips MF, Quinlivan RC, Edwards RH, et al. . Changes in spirometry over time as a prognostic marker in patients with duchenne muscular dystrophy. Am J Respir Crit Care Med 2002; 164: 2191–2194.
    1. Gayraud J, Ramonatxo M, Rivier F, et al. . Ventilatory parameters and maximal respiratory pressure changes with age in Duchenne muscular dystrophy patients. Pediatr Pulmonol 2010; 45: 552–559.
    1. Tangsrud S, Petersen IL, Lødrup Carlsen KC, et al. . Lung function in children with Duchenne’s muscular dystrophy. Respir Med 2001; 95: 898–903.
    1. Grippi MA, Elias JA, Fishman JA. et al. eds. Fishman’s Pulmonary Diseases and Disorders. 5th Edn. New York, McGraw-Hill Medical, 2015.
    1. Parsons SJ, McMurtrie A, Cooke S, et al. . Facioscapulohumeral muscular dystrophy assessment and treatment. Orthop Trauma 2009; 23: 180–185
    1. Hutchinson D, Whyte K. Neuromuscular disease and respiratory failure. Pract Neurol 2008; 8: 229–237.
    1. Fayssoil A, Ogna A, Chaffaut C, et al. . Natural history of cardiac and respiratory involvement, prognosis and predictive factors for long-term survival in adult patients with limb girdle muscular dystrophies type 2C and 2D. PLoS One 2016; 11: e0153095.
    1. Takahashi T, Aoki M, Suzuki N, et al. . Clinical features and a mutation with late onset of limb girdle muscular dystrophy 2B. J Neurol Neurosurg Psychiatr 2013; 84: 433–440.
    1. Ho G, Cardamone M, Farrar M. Congenital and childhood myotonic dystrophy: Current aspects of disease and future directions. World J Clin Pediatr 2015; 4: 66–80.
    1. Bourke SC, Gibson GJ. Sleep and breathing in neuromuscular disease. Eur Respir J 2002; 19: 1194–1201.
    1. Romeo V. Myotonic dystrophy type 1 or Steinert’s disease. Adv Exp Med Biol 2012; 724: 239–257.
    1. Bogaard JM, van der Meché FG, Hendriks I, et al. . Pulmonary function and resting breathing pattern in myotonic dystrophy. Lung 1992; 170: 143–153.
    1. Gilmartin JJ, Cooper BG, Griffiths CJ, et al. . Breathing during sleep in patients with myotonic dystrophy and non-myotonic respiratory muscle weakness. Q J Med 1991; 78: 21–31.
    1. Durmus H, Laval SH, Deymeer F, et al. . Oculopharyngodistal myopathy is a distinct entity: clinical and genetic features of 47 patients. Neurology 2011; 76: 227–235.
    1. Witting N, Mensah A, Køber L, et al. . Ocular, bulbar, limb, and cardiopulmonary involvement in oculopharyngeal muscular dystrophy. Acta Neurol Scand 2014; 130: 125–130.

Source: PubMed

3
Předplatit